Fluicell AB (publ) (STO:FLUI)
29.60
+1.30 (4.59%)
May 21, 2026, 11:58 AM CET
Fluicell AB Revenue
Fluicell AB had revenue of 8.42M SEK in the quarter ending March 31, 2026, with 217.46% growth. This brings the company's revenue in the last twelve months to 20.06M, up 133.04% year-over-year. In the year 2025, Fluicell AB had annual revenue of 15.22M with 184.54% growth.
Revenue (ttm)
20.06M
Revenue Growth
+133.04%
P/S Ratio
1.94
Revenue / Employee
1.82M
Employees
11
Market Cap
38.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.22M | 9.87M | 184.54% |
| Dec 31, 2024 | 5.35M | 2.01M | 60.25% |
| Dec 31, 2023 | 3.34M | 87.00K | 2.68% |
| Dec 31, 2022 | 3.25M | 649.00K | 24.94% |
| Dec 31, 2021 | 2.60M | -2.03M | -43.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Alzinova AB | 25.66M |
| Scandinavian ChemoTech AB | 12.61M |
| Spago Nanomedical AB | 4.38M |
| OncoZenge AB | 2.78M |
| Aptahem AB | 2.59M |
| Biosergen AB | 2.09M |
| 2cureX AB | 1.98M |
| Pila Pharma AB | 1.13M |